CTVA Stock Analysis: Corteva | NYSE
Agricultural Inputs | NYSE, USA | Market Cap: 55.978m USD | 12M Return: 22.1% | US22052L1044 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 345M
EPS Trend: 85.8%
Qual. Beats: 0
Rev. Trend: 61.3%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
Seasonality 7.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Corteva, Inc. (NYSE: CTVA) is a U.S.-based agricultural inputs company that operates through two segments: Seed and Crop Protection. The Seed segment supplies advanced germplasm and traits designed to improve yield, along with digital decision-support tools for farmers. The Crop Protection segment provides herbicides, insecticides, nitrogen stabilizers, and pasture and range management products that protect and enhance crop health. Corteva sells to the global agricultural input industry across the United States, Canada, Latin America, Asia Pacific, Europe, the Middle East, and Africa, and is headquartered in Indianapolis, Indiana.
Corteva was spun off from DowDuPont and began trading on the NYSE in May 2019, which is why the company carries an 1802 founding date tied to its predecessor heritage while its standalone public history is more recent. The Seeds and Crop Protection market is a concentrated industry dominated by a handful of large multinational players, and Cortevas vertically integrated model combines germplasm development, trait licensing, and crop chemistry with R&D-heavy product cycles typical of the agricultural inputs sector.
- Latin America planting season drives Seed volume and pricing
- Crop Protection margins face generic competition pressure
- Capital return program expands through accelerated share buybacks
| Net Income: 1.01b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -4.70 > 1.0 |
| NWC/Revenue: 31.26% < 20% (prev 37.77%; Δ -6.51% < -1%) |
| CFO/TA 0.03 > 3% & CFO 1.21b > Net Income 1.01b |
| Net Debt (2.51b) to EBITDA (3.24b): 0.77 < 3 |
| Current Ratio: 1.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (671.6m) vs 12m ago -1.68% < -2% |
| Gross Margin: 48.45% > 18% (prev 45.65%; Δ 2.80% > 0.5%) |
| Asset Turnover: 42.71% > 50% (prev 41.13%; Δ 1.58% > 0%) |
| Interest Coverage Ratio: 11.43 > 6 (EBIT TTM 2.00b / Interest Expense TTM 175.0m) |
| A: 0.13 (Total Current Assets 16.4b - Total Current Liabilities 10.8b) / Total Assets 41.6b |
| B: 0.03 (Retained Earnings 1.22b / Total Assets 41.6b) |
| C: 0.05 (EBIT TTM 2.00b / Avg Total Assets 41.7b) |
| D: 1.55 (Book Value of Equity 25.2b / Total Liabilities 16.2b) |
| Altman-Z'' = 2.92 = A |
| DSRI: 0.97 (Receivables 8.70b/8.67b, Revenue 17.8b/17.2b) |
| GMI: 0.94 (GM 45.65% / 48.45%) |
| AQI: 0.72 (AQ_t 0.37 / AQ_t-1 0.52) |
| SGI: 1.04 (Revenue 17.8b / 17.2b) |
| TATA: -0.00 (NI 1.01b - CFO 1.21b) / TA 41.6b) |
| Beneish M = -3.24 (Cap -4..+1) = AA |
As of September 05, 2026, the stock is trading at USD 87.86 with a total of 4,165,601 shares traded. Over the past week, the price has changed by +4.94%, over one month by +12.43%, over three months by +13.67% and over the past year by +22.07%.
Current recommended Stop Loss: 84.90 (which is 3.4% or 1.3 ATR below the current price).
Corteva has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy CTVA.
- StrongBuy: 13
- Buy: 5
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 92.1 | 4.8% |
P/E Trailing = 49.9405
P/E Forward = 23.2019
P/S = 3.1427
P/B = 2.1852
P/EG = 1.3207
Revenue TTM = 17.8b USD
EBIT TTM = 2.00b USD
EBITDA TTM = 3.24b USD
Long Term Debt = 1.69b USD (from longTermDebt, last fiscal year)
Short Term Debt = 3.19b USD (from shortTermDebt, last quarter)
Debt = 4.88b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.51b USD (calculated: Debt 4.88b - CCE 2.37b)
Enterprise Value = 58.5b USD (56.0b + Debt 4.88b - CCE 2.37b)
Interest Coverage Ratio = 11.43 (Ebit TTM 2.00b / Interest Expense TTM 175.0m)
EV/FCF = 92.99x (Enterprise Value 58.5b / FCF TTM 629.0m)
FCF Yield = 1.08% (FCF TTM 629.0m / Enterprise Value 58.5b)
FCF Margin = 3.53% (FCF TTM 629.0m / Revenue TTM 17.8b)
Net Margin = 5.66% (Net Income TTM 1.01b / Revenue TTM 17.8b)
Gross Margin = 48.45% ((Revenue TTM 17.8b - Cost of Revenue TTM 9.18b) / Revenue TTM)
Gross Margin QoQ = 54.35% (prev 51.64%)
Tobins Q-Ratio = 1.40 (Enterprise Value 58.5b / Total Assets 41.6b)
Interest Expense / Debt = 3.59% (Interest Expense 175.0m / Debt 4.88b)
Taxrate = 30.70% (486.0m / 1.58b)
NOPAT = 1.39b (EBIT 2.00b * (1 - 30.70%))
Current Ratio = 1.52 (Total Current Assets 16.4b / Total Current Liabilities 10.8b)
Debt / Equity = 0.19 (Debt 4.88b / totalStockholderEquity, last quarter 25.2b)
Debt / EBITDA = 0.77 (Net Debt 2.51b / EBITDA 3.24b)
Debt / FCF = 3.99 (Net Debt 2.51b / FCF TTM 629.0m)
Total Stockholder Equity = 24.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.42% (Net Income 1.01b / Total Assets 41.6b)
RoE = 4.08% (Net Income TTM 1.01b / Total Stockholder Equity 24.7b)
RoCE = 7.58% (EBIT 2.00b / Capital Employed (Equity 24.7b + L.T.Debt 1.69b))
RoIC = 4.18% (NOPAT 1.39b / Invested Capital 33.2b)
WACC = 6.43% (E(56.0b)/V(60.9b) * Re(6.77%) + D(4.88b)/V(60.9b) * Rd(3.59%) * (1-Tc(0.31)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.51 | Cagr: -2.00%
[DCF] Terminal Value 73.10% ; FCFF base≈1.42b ; Y1≈1.24b ; Y5≈1.00b
[DCF] Fair Price = 20.36 (EV 16.1b - Net Debt 2.51b = Equity 13.6b / Shares 667.2m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 85.83 | EPS CAGR: 16.84% | SUE: 0.33 | # QB: 0
Revenue Correlation: 61.30 | Revenue CAGR: 1.58% | SUE: -0.86 | # QB: -1
EPS current Quarter (2026-09-30): EPS=-0.39 | Chg30d=-41.28% | Revisions=-56% | Analysts=15
EPS current Year (2026-12-31): EPS=3.76 | Chg30d=+0.08% | Revisions=+39% | GrowthEPS=+12.7% | GrowthRev=+4.1%
EPS next Year (2027-12-31): EPS=3.40 | Chg30d=-0.95% | Revisions=-17% | GrowthEPS=+32.5% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: -9% (up=14, down=17)